

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

Notices

- License integration enhancement has been postponed. The launch was not successful
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- The RFP for the PDMP contract has been issued; proposals are due November 5, 2020.
- The PDMP received two grants: The State Opioid Response (SOR) grant and a partial award of the Bureau of Justice Assistance (BJA) grant.

Registration

Portal

Number of licensed Pharmacists: 1,187
Number of PDMP Pharmacist registrations: 777
Number of Pharmacists dispensing: 672
Compliance rate: 116%

AWARxE (PDMP)

Number registered with the PDMP: 809
Compliance rate: 120%

Delinquent Reporters

Providers who directly dispense are required to report daily. Currently, there are 285 delinquent submitters in AWARxE. This number includes all dispensers, not just pharmacies.

Recommendations

- Encourage increased reviewing, including the use of delegates
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.

**PDMP Overview
 Registration**




Figure 1A. Physician includes those registered as Physician, Podiatrist, and Medical Residents with Prescriptive Authority. *Other includes IHS, VA, and military prescribers and dispensers, admin, coroners, and out-of-state pharmacists.




Figure 1B. This figure may be underrepresented as there are licensed prescribers inclusive in federal user role categories (IHS Prescriber, VA Prescriber, and Military Prescribers).

Alaska Prescription Drug Monitoring Program
 Summary Prepared for the Board of Pharmacy
 November 2020



MME Use

June 2020 – October 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDC_06.2018.pdf

CDC guidelines for prescribing opioids for chronic pain -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDCPain_2018.10.pdf

Provider Type	# Providers Prescribing at Least Once	# Providers Who Reviewed 0 Patients	# Providers Prescribing >90MME	# Providers Prescribing >120MME	Dangerous Combo	
					Benzo Opioid	Benzo Opioid Carisoprodol
NUR	499	22% (112)	12% (59)	7% (37)	25% (124)	1% (7)
DEN	311	60% (187)	5% (17)	1% (4)	26% (80)	0
MED	1354	31% (421)	20% (273)	12% (165)	32% (438)	2.6% (35)
VET	171	76% (130)	2% (4)	2% (4)	6% (10)	0
OPT	2	100% (2)	0	0	0	0